Our scientists are excited to announce our first true tumor-specific T cell line! Our new anti-leukemia T cells have many applications in immunotherapy research.
Why an Anti-Leukemia T Cell?
Our newest T cell line recognizes the WT1 tumor antigen. WT1 gets its name from a gene that was originally discovered in Wilms’ tumor, a type of kidney malignancy affecting 1 in 10,000 infants.
Since its discovery, scientists have found the WT1 antigen to be overexpressed in many tumors, including acute myelocytic, acute lymphocytic, and chronic myelocytic leukemia, and several solid tumors, including lung cancer and breast cancer. This widespread overexpression makes WT1 an attractive target for immunotherapy research and for developing WT1-based T cell therapies.
In fact, the National Cancer Institute (NCI) ranked the WT1 antigen as the top target for cancer immunotherapy.1
We have not yet tested these anti-leukemia T cells for their ability to recognize specific tumor cells; we’ve left that for you to try!
In addition to the anti-leukemia T cells, we also have the corresponding WT1 peptide for your research needs.